
Evaluation of Hair Growth Stimulation via PDO Polydioxanone Thread Application: An Observational Pilot Study

Alan J Bauman, MD, ABHRS, FISHRS

Bauman Medical Hair Transplant & Hair Loss Treatment Center | Boca Raton, FL | USA 33rd World Congress of the ISHRS | October 23-25, 2025 | Berlin



@DrAlanBauman

Introduction

- Androgenetic alopecia (AGA) impacts self-esteem and QoL.
- Current therapies (minoxidil, finasteride, LLLT, PRP, surgery) vary in effectiveness and compliance.
- PDO threads, FDA-cleared as surgical sutures since the 1980s, are biocompatible and biodegradable.
- Prior studies in humans and mice (Bharti 2017, Seo 2015). suggest PDO may stimulate hair growth through regenerative mechanisms.
- This pilot study investigates safety, feasibility, and hair regrowth outcomes.



Smooth PDO thread (29g)

Methods

Participants (n=4):

Males (NW5, NW6) and females (frontal/vertex thinning), ages 45–58 w/ AGA. No hair therapy or surgery.


Procedure:

Local anesthesia block + ProNox. Radial/parallel PDO thread insertion, 0.5-1.0cm spacing.

Thread sizes: 29g [25mm + 38mm]

Assessment tools & timing:

- Global photography
- Trichoscopy
- Hair Mass Index (HMI)
- Baseline, W6, W12, M6, M9, M12



Careful placement of PDO threads in the subq space below the follicles and above the galea avoids follicular damage.



Intraoperative view of PDO thread placement

Results

- All patients showed increased density, thickness, and HMI.
- Example: One patient achieved +48% HMI at 6 months.
- Photography: Visible coverage improvement.
- Trichoscopy: Increased terminal hair counts, length, pigment, and caliber.
- Animal models confirm PDO enhances anagen phase, proliferation, and vascularization.

Results (con't)

CASE #1: Female, Hairline/Temple Thinning



52年AGA % thinning x 10yrs h/o knee surgery, no current hair txs. 63 PDO threads (29g) Hairline/temples to Midscalp Photos: BL, M6; HMI: BL, W6, W12 Midscalp responded faster than temples. Temple coverage improved.



CASE #2: Female, Vertex Thinning



51\$AGA % thinning crown x 5yrs, h/o menopause, no current hair txs. 38 PDO threads (29g), Vertex Photos: BL, M6; HMI: BL, M3, M6; 48% 1 HMI at M6



CASE #3: Male, NW5-6



45 NW5-6, no meds/no PMHx/no SxHx. 40 PDO Threads (29g), Front to Vertex Photos: BL, M6; HMI: BL, M3, M6. Frontal coverage improved, part-width decreased.

CASE #4: Male, NW6



58 NW6, no hair meds, no surgery. h/o testosterone use, Ca+ channel blocker for HTN, 40 PDO Threads (29g), Front to Vertex plus 7.0cc of PRP + perinatal ECM tissue Photos & HMI: BL, M3, M6, M9

HMI increase lasted ~6-9mos





Trichoscopy BL vs. M6: †length, †thickness & †pigmentation of miniaturized hair in all areas.

Discussion

PDO threads may act through:

- Neo-collagenesis
- Improved blood supply
- Growth factor modulation (†FGF-7, ↓FGF-5)

Safety:

Mild transient erythema, tenderness; rare extrusion.

Limitations:

Small observational cohort (n=4), no control group.

Larger controlled studies are needed to refine protocols, determine optimal timing for repeat treatments, and assess broader patient populations.

Take-Home Message

PDO threads stimulate clinically significant hair regrowth by enhancing the anagen phase, improving vascularization, and supporting follicular proliferation.

They represent a safe, promising, minimally invasive, nonpharmaceutical option for managing AGA.

Conclusion

- PDO threads are a promising, minimally invasive, nonpharmacological, regenerative hair growth treatment.
- Can be used as standalone or adjunct to PRP, Exosomes, or FUE.
- Demonstrated strong safety profile and patient tolerance.

References

Middleton JC, Tipton AJ. *Qmed.com*, 1998. Seo HS, et al. *J Pharmacopuncture*, 2015. Bharti S, et al. JEADV, 2017. Bauman AJ. PDO Hair Growth, SBS 2019. Yoon JH, Kim SS, et al. *J Cosmet Dermatol*, 2019. Bauman AJ. TED + PDO Hair Growth, IMCAS 2023.





Thank you to the entire talented and passionate Bauman Medical team!